Cynshi O, Kawabe Y, Suzuki T, Takashima Y, Kaise H, Nakamura M, Ohba Y, Kato Y, Tamura K, Hayasaka A, Higashida A, Sakaguchi H, Takeya M, Takahashi K, Inoue K, Noguchi N, Niki E, Kodama T
Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan.
Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10123-8. doi: 10.1073/pnas.95.17.10123.
Antioxidants have been proposed to have antiatherogenic potential by their inhibition of low density lipoprotein (LDL) oxidation. Here, we report an antioxidant, BO-653 (2,3-dihydro-5-hydroxy-2, 2-dipentyl-4,6-di-tert-butylbenzofuran), designed to exhibit antioxidative potency comparable to that of alpha-tocopherol, but yet possess a high degree of lipophilicity comparable to that of probucol. BO-653 exhibits a high affinity for LDL and is well distributed in aortic vessels in vivo. In atherosclerosis models of rabbits and mice, BO-653 has been shown to be able to suppress the formation of atherosclerotic lesions without untoward side effects. Specifically, there was no reduction of high density lipoprotein levels. This antioxidant provides additional evidence in support of the oxidized-LDL hypothesis, and itself is a promising candidate antioxidant for clinical use.
抗氧化剂已被提出因其对低密度脂蛋白(LDL)氧化的抑制作用而具有抗动脉粥样硬化潜力。在此,我们报告一种抗氧化剂BO - 653(2,3 - 二氢 - 5 - 羟基 - 2,2 - 二戊基 - 4,6 - 二叔丁基苯并呋喃),其设计目的是展现出与α - 生育酚相当的抗氧化效力,但同时具有与普罗布考相当的高度亲脂性。BO - 653对LDL具有高亲和力,且在体内能很好地分布于主动脉血管中。在兔和小鼠的动脉粥样硬化模型中,BO - 653已被证明能够抑制动脉粥样硬化病变的形成且无不良副作用。具体而言,高密度脂蛋白水平没有降低。这种抗氧化剂为氧化LDL假说提供了额外证据,其本身是一种有前景的临床用抗氧化剂候选物。